Licoisoflavone A
CAS No. : 66056-19-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $310 | In-stock |
| 10mg | $465 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N3389 |
| M.Wt: | 354.35 |
| Formula: | C20H18O6 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC50 of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection[1][2][3][4].
In Vitro:Licoisoflavone A (0-100 μM) inhibits RNA-dependent RNA polymerase (RdRp) and cAMP-specific 3’,5’-cyclic phosphodiesterase 4 (PDE4) with IC50 values of 47.31 μM and 1.77 μM, respectively[1].
Licoisoflavone A (5 μM, 2 days) significantly reduces the cross-sectional area of Ang II-induced hypertrophic H9c2 cells by approximately 46%[2].
Licoisoflavone A (15 μM, 48 h) upregulates Sirt3 expression and reduces MnSOD acetylation at K68 in PE-induced neonatal rat cardiomyocytes[2].
Licoisoflavone A (15 μM, 48 h) decreases relative ANF and BNP levels in Phenylephrine (PE) (HY-B0769)-induced hypertrophic cardiac cells, but this effect is blocked when co-treated with Sirt3 inhibitor 3-TYP (HY-108331)[2].
Licoisoflavone A ( 6.25-25 μM, 48 h) significantly inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in HCT116 and SW480 colorectal cancer (CRC) cells[4].
Licoisoflavone A (6.25-25 μM, 48 h) downregulates CDK2, Cyclin E1, and phosphorylated Rb (p-Rb) while upregulating p27 in HCT116 and SW480 cells, inhibiting the CDK2-Cyclin E1 axis[4].
Licoisoflavone A (1-1000000 nM, 3 days) dose-dependently inhibits viability of 5 patient-derived CRC organoids (CRCOs) with IC50 values ranging from 7.02 to 82.98 μM, and shows lower toxicity to normal colorectal organoids (CNOs)[4].
In Vivo:Licoisoflavone A (25-50 mg/kg, p.o., daily, 2 weeks) exhibits significant anti-tumor efficacy in BALB/c mice bearing CT26 cell subcutaneous xenografts [4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Licoisoflavone A
- Cat. No.:
- HY-N3389
- Quantity:
Your information is safe with us.